BusinessVBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) PatientsBy Nasdaq OMXApr 17, 2018, 12:01 PM UTC
BusinessVBI Vaccines Announces Changes to its Board of DirectorsBy Nasdaq OMXJan 26, 2018, 9:15 PM UTC
BusinessVBI Vaccines Announces Initiation of Phase 3 Clinical Program for Sci-B-Vac® Hepatitis B VaccineBy Nasdaq OMXDec 19, 2017, 1:00 PM UTC
BusinessVBI Vaccines to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare ConferenceBy Nasdaq OMXDec 12, 2017, 1:00 PM UTC
BusinessVBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017By Nasdaq OMXNov 10, 2017, 1:00 PM UTC
BusinessVBI Vaccines Strengthens Board of Directors with Appointment of Ran NussbaumBy Nasdaq OMXNov 2, 2017, 12:02 PM UTC
BusinessVBI Vaccines Announces Closing of Public Offering and Concurrent Registered Direct Offering of Common SharesBy Nasdaq OMXOct 31, 2017, 12:31 PM UTC
